BIO FY 2025 Earnings Report — Bio-Rad Laboratories, Inc. Revenue & Financial Results | Market Cap Arena

Bio-Rad Laboratories, Inc.BIO

FY 2025 Earnings

Reported February 12, 2026

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2025	Prior Q	FY 2024	QoQ Change	YoY Change
Revenue	$2.6B	—	$2.6B	—	0.7%
Op. Income	$271M	—	$269M	—	0.6%
Gross Margin	52.0%	—	53.7%	—	-1.7pp
Net Margin	29.4%	—	-71.9%	—	101.3pp
EPS (Diluted)	$27.87	—	$-65.36	—	142.6%
Free Cash Flow	$375M	—	$266M	—	40.7%

Revenue Flow

Item	Amount
REVENUE	$2.6B
Cost of Revenue	$1.2B
GROSS PROFIT	$1.3B
R&D Expenses	$257M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$820M
Other Expenses	$0
Operating Expenses	$1.1B
Cost & Expenses	$2.3B
OPERATING INCOME	$271M
Interest Income	$96M
Interest Expense	$49M
Other Income/Expenses	$725M
INCOME BEFORE TAX	$996M
Income Tax Expense	$236M
Net Income from Continuing Ops	$760M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$760M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$760M
D&A	$205M
EBIT	$271M
EBITDA	$476M
EPS	$28
EPS Diluted	$28

Income Statement

Item	Amount
REVENUE	$2.6B
Cost of Revenue	$1.2B
GROSS PROFIT	$1.3B
R&D Expenses	$257M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$820M
Other Expenses	$0
Operating Expenses	$1.1B
Cost & Expenses	$2.3B
OPERATING INCOME	$271M
Interest Income	$96M
Interest Expense	$49M
Other Income/Expenses	$725M
INCOME BEFORE TAX	$996M
Income Tax Expense	$236M
Net Income from Continuing Ops	$760M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$760M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$760M
D&A	$205M
EBIT	$271M
EBITDA	$476M
EPS	$28
EPS Diluted	$28

Cash Flow Statement

Item	Amount
Net Income	$760M
Depreciation & Amortization	$205M
Stock-Based Compensation	$0
Deferred Income Tax	$171M
Other Non-Cash Items	-$879M
Change in Working Capital	$276M
OPERATING CASH FLOW	$532M
Capital Expenditure	-$158M
Acquisitions (Net)	-$218M
Purchases of Investments	-$669M
Sales/Maturities of Investments	$62M
Other Investing Activities	$794M
NET CASH FROM INVESTING	-$190M
Net Debt Issuance	-$500.0K
Common Stock Repurchased	-$296M
Common Dividends Paid	$0
Other Financing Activities	-$3M
NET CASH FROM FINANCING	-$283M
FREE CASH FLOW	$375M
Net Change in Cash	$40M

Balance Sheet

Item	Amount
Cash & Equivalents	$532M
Short-Term Investments	$1.0B
Net Receivables	$473M
Inventory	$741M
Other Current Assets	$14M
TOTAL CURRENT ASSETS	$2.9B
PP&E (Net)	$710M
Goodwill	$580M
Intangible Assets	$174M
Long-Term Investments	$6.1B
Tax Assets	$0
Other Non-Current Assets	$102M
TOTAL NON-CURRENT ASSETS	$7.7B
TOTAL ASSETS	$10.6B
Account Payables	$129M
Short-Term Debt	$38M
Deferred Revenue	$0
Other Current Liabilities	$141M
TOTAL CURRENT LIABILITIES	$517M
Long-Term Debt	$1.3B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$1.1B
Other Non-Current Liabilities	$53M
TOTAL NON-CURRENT LIABILITIES	$2.6B
TOTAL LIABILITIES	$3.1B
Common Stock	$0
Additional Paid-In Capital	$476M
Retained Earnings	$8.2B
Treasury Stock	-$1.0B
Accum. Other Comp. Income	-$189M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$7.5B
Minority Interest	$0
TOTAL EQUITY	$7.5B
TOTAL LIABILITIES & EQUITY	$10.6B
Total Debt	$1.5B
Net Debt	$999M